Circulating Tumor Cell Count
0093399
Ordering Recommendation
May use to predict survival in patients treated for metastatic breast, prostate, and colorectal cancers. May use to evaluate response to therapy.
Submit With Order
Mnemonic
CTC COUNT
Methodology
Immunomagnetic Separation/Immunofluorescent Stain/Computer Assisted Analysis
Performed
Wed-Fri
Reported
1-5 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
If the patient is on doxorubicin therapy, allow at least 7 days following administration of a dose of doxorubicin before blood draw.  
Collect
CellSave®Preservative tube (ARUP supply # 44867). Available online through eSupply using ARUP ConnectTM or contact
ARUP Client Services at (800) 522-2787. Due to stability, collect Monday-Thursday only.  
Specimen Preparation
Transport 20 mL whole blood. (Min: 10 mL) The minimum collection amount will not allow for repeat testing.  
Storage/Transport Temperature
Room temperature. Do not refrigerate or freeze.  
Unacceptable Conditions
Frozen or refrigerated specimens. Specimens not collected in the CellSave® tube or collected in expired CellSave® tubes. Short draws.  
Remarks
REQUIRED ORDER INFORMATION: Source of metastatic cancer breast, colorectal, or prostate. This assay is FDA approved only for these 3 metastatic cancers; other types will not be tested.  
Stability
Ambient: 4 days; Refrigerated: Unacceptable; Frozen: Unacceptable  
Reference Interval
By report
Interpretive Data
Refer to report.

For additional information, refer to the Breast Cancer Management Assays, Prostate Cancer, or Colorectal Cancer topic at arupconsult.com.
Note
The CellSearch™ Circulating Tumor Cell kit is intended for the quantification of circulating tumor cells (CTC) of epithelial origin for metastatic breast, colon, or prostate cancer, in whole blood. This assay can be used to predict progression free and overall survival in patients treated for metastatic cancer.

The results of a CellSearch™ test should be interpreted with caution if specimens are drawn within 7 days of administration of doxorubicin therapy.
CPT Code(s)
86152
Components
Component Test Code*Component Chart Name
0093400Circulating Tumor Cell Number
0093401Patient History - Metastatic Cancer Type
2007444EER Circulating Tumor Cell Count
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • Cell Search
  • Circulating Tumor Cells, Breast, Colon, Prostate
  • CTC